3 Active Ingredients and Custom Manufacturing, Biologics and Formulations and Research-Led CDMO Stocks With a Strong Future Roadmap: Neuland Laboratories, Shilpa Medicare and Anthem Biosciences
- October 23, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Neuland Laboratories, Shilpa Medicare and Anthem Biosciences: ROE of 9.4% to 19.4% and FY22 to FY26 revenue CAGR of 7.5% to 21.1%. Prices as of 22 Oct 2026.
Quick Answer
The three contract manufacturing and API innovator stocks to watch are Neuland Laboratories, Shilpa Medicare and Anthem Biosciences. Their return on equity ranges from 9.4% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.5% to 21.1%. Anthem Biosciences has the highest return on equity at 19.4%, while Neuland Laboratories has the fastest revenue growth at 21.1% a year. Prices are based on the 22 October 2026 close, and this article is educational, not investment advice.
Contract manufacturing and API innovator stocks let investors follow companies that help global drug makers develop and produce medicines. Neuland Laboratories, Shilpa Medicare and Anthem Biosciences cover active ingredients and custom manufacturing, biologics and formulations and a research-led contract development and manufacturing organisation.
This list covers three contract manufacturing and API innovator stocks with complete current figures: Neuland Laboratories, Shilpa Medicare and Anthem Biosciences. Every figure comes from the latest reported financials and the 22 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Contract Manufacturing and API Innovator Stocks?
Contract manufacturing and API innovator stocks are listed companies that make active ingredients and run contract development and manufacturing for pharma and biotech clients. Their earnings depend on project wins, capacity and long-term supply contracts.
Contract Manufacturing and API Innovator Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Neuland Laboratories | 18,935 | 24,665 | 49.5 | 36.0 | 19.4 | 0.16 |
| Shilpa Medicare | 860.8 | 17,132 | 57.6 | 36.0 | 9.4 | 0.25 |
| Anthem Biosciences | 800.75 | 45,546 | 79.1 | 36.0 | 19.4 | 0.02 |
On valuation, all three trade at a P/E above their industry P/E, which reflects the growth the market already expects from them. Readers comparing contract manufacturing and API innovator stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Contract Manufacturing and API Innovator Stocks Have a Strong Roadmap in India?
Contract manufacturing and API innovator stocks have a strong roadmap in India because global drug makers are widening supply chains beyond a few countries and favour partners with strong chemistry and quality records.
- Supply chain shift. Global clients add Indian partners for reliable supply.
- Long contracts. Multi-year projects give visibility on revenue.
- Research depth. Skilled chemists win complex, high-value work.
Why Neuland Laboratories Features Among These Contract Manufacturing and API Innovator Stocks
Among the contract manufacturing and API innovator stocks on this list, Neuland Laboratories, based in Hyderabad, makes active pharmaceutical ingredients for generic drugs and runs a custom manufacturing business that supplies innovator companies.
Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%.
The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0.
Roadmap: The company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.
What to watch: Custom manufacturing revenue can move between quarters, so review the full-year trend.
Why Shilpa Medicare Features Among These Contract Manufacturing and API Innovator Stocks
Among the pharma outsourcing company shares on this list, Shilpa Medicare, headquartered in Raichur, Karnataka, is a pharmaceutical company with active ingredients, formulations, biologics and contract development and manufacturing under one roof, with a focus on oncology.
The company has a return on equity of 9.4%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 17,132 crore. The stock trades at a P/E of 57.6, above the industry P/E of 36.0.
Revenue rose from Rs 1,160 crore in FY22 to Rs 1,549 crore in FY26, a compound annual growth rate of 7.5%. Net profit grew from Rs 60.6 crore in FY22 to Rs 243 crore in FY26, which works out to a compound annual growth rate of 41.6%. In the June 2026 quarter, revenue grew 43.0% year on year to Rs 469 crore, while net profit rose 115.1% to Rs 101 crore.
Roadmap: Its path forward combines a growing biologics and specialty injectables pipeline with contract manufacturing for global partners. Multiple business lines give it more than one route to scale as regulatory approvals arrive.
What to watch: Follow regulatory approvals and commercial launches, since these drive the timing of earnings.
Why Anthem Biosciences Features Among These Contract Manufacturing and API Innovator Stocks
Among the three companies on this list, Anthem Biosciences is a research-driven contract development and manufacturing organisation that serves global pharma and biotech customers with discovery, development and manufacturing services.
Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%.
The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0.
Roadmap: The company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.
What to watch: Monitor the order pipeline from global customers and the ramp-up of newer manufacturing capacity.
Neuland Laboratories vs Shilpa Medicare vs Anthem Biosciences on Key Financials
The table below sets the three contract manufacturing and API innovator stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Neuland Laboratories | 953 | 2,053 | 21.1% | 364 | 17.7% |
| Shilpa Medicare | 1,160 | 1,549 | 7.5% | 243 | 15.7% |
| Anthem Biosciences | 1,280 | 2,280 | 15.5% | 592 | 26.0% |
Anthem Biosciences posts the highest return on equity in this group at 19.4%. Anthem Biosciences has the largest FY26 revenue at Rs 2,280 crore, and Neuland Laboratories shows the fastest revenue growth with a 21.1% compound annual rate. A useful habit with contract manufacturing and API innovator stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Contract Manufacturing and API Innovator Stocks
Every theme carries risks that deserve a check before any decision. For these contract manufacturing and API innovator stocks, the main points are:
- Project timing. Customer projects can start or shift between quarters.
- Client concentration. A few large customers can account for a major share of sales.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter contract manufacturing and API innovator stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Contract Manufacturing and API Innovator Stocks
Contract manufacturing and API innovator stocks reward investors who follow project wins, capacity and client additions together. Neuland Laboratories, Shilpa Medicare and Anthem Biosciences each have a clear path to growth. Based on the 22 October 2026 close, Neuland Laboratories trades at Rs 18,935, Shilpa Medicare at Rs 860.8 and Anthem Biosciences at Rs 800.75.
Download the Univest iOS App or Univest Android App to track contract manufacturing and API innovator stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are contract manufacturing and API innovator stocks?
Ans. Contract manufacturing and API innovator stocks are listed companies that make active ingredients and run contract development and manufacturing for pharma and biotech clients. Their earnings depend on project wins, capacity and long-term supply contracts. This list looks at three of them, Neuland Laboratories, Shilpa Medicare and Anthem Biosciences, using reported FY22 to FY26 financials and the 22 October 2026 closing prices.
Which contract manufacturing and API innovator stocks are covered in this list?
Ans. This list covers Neuland Laboratories, Shilpa Medicare and Anthem Biosciences. Based on the 22 October 2026 close, Neuland Laboratories traded at Rs 18,935, Shilpa Medicare at Rs 860.8 and Anthem Biosciences at Rs 800.75. Their return on equity ranges from 9.4% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.5% to 21.1%.
Why do contract manufacturing and API innovator stocks have a strong future roadmap in India?
Ans. Contract manufacturing and API innovator stocks have a strong roadmap in India because global drug makers are widening supply chains beyond a few countries and favour partners with strong chemistry and quality records. The main drivers are as follows. Supply chain shift. Global clients add Indian partners for reliable supply. Long contracts. Multi-year projects give visibility on revenue. Research depth. Skilled chemists win complex, high-value work. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Neuland Laboratories performed financially?
Ans. Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0. Looking ahead, the company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.
How has Shilpa Medicare performed financially?
Ans. Revenue rose from Rs 1,160 crore in FY22 to Rs 1,549 crore in FY26, a compound annual growth rate of 7.5%. Net profit grew from Rs 60.6 crore in FY22 to Rs 243 crore in FY26, which works out to a compound annual growth rate of 41.6%. In the June 2026 quarter, revenue grew 43.0% year on year to Rs 469 crore, while net profit rose 115.1% to Rs 101 crore. The company has a return on equity of 9.4%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 17,132 crore. The stock trades at a P/E of 57.6, above the industry P/E of 36.0. Looking ahead, its path forward combines a growing biologics and specialty injectables pipeline with contract manufacturing for global partners. Multiple business lines give it more than one route to scale as regulatory approvals arrive.
How has Anthem Biosciences performed financially?
Ans. Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0. Looking ahead, the company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.
What risks should investors check before buying contract manufacturing and API innovator stocks?
Ans. Investors should check a few risks before buying contract manufacturing and API innovator stocks. Project timing. Customer projects can start or shift between quarters. Client concentration. A few large customers can account for a major share of sales. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of contract manufacturing and API innovator stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 22 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
